Symbol | Exchange | Currency |
|---|
Bristol Myers Squibb Co. said Thursday it had a net loss of $10.027 billion, or $4.45 a share, in the fourth quarter, wider than the loss of $1.056 billion, or 55 cents a share,...
On the 31st of December, the T. Rowe Price Equity Income Fund sold 9.7 million MGM Resorts International (NYSE:MGM) shares for $305 million at an average price of $31.51 per share....
On the 31st of December, the T. Rowe Price Equity Income Fund bought 7 million Yum Brands Inc (YUM) shares for $755 million at an average price of $108.56 per share. Shares of Yum...
Pharmaceutical companies are a compelling option for long-term investors to consider at this time, especially given the important role that they continue to play in the global...
While Bristol-Myers Squibb (NYSE:BMY) isn't exactly lacking in reasons to consider it a household name, it recently figured that it could stand a little extra firepower on its...
1. AbbVie (NYSE:ABBV), a biopharma research company, had a nice pop on Tuesday after reaching a session high of 92.23, and gaining 2.56, or 2.9%, to 90.46, on 22 million shares...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | |||||
| Technical Indicators | |||||
| Summary |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 313.85 | 330.17 | 312.93 | -14.84 | -4.51% | 38.06M | NASDAQ | |||
| 149.59 | 150.84 | 149.02 | +0.95 | +0.64% | 32.82M | NASDAQ | |||
| 2,780.00 | 2,800.30 | 2,767.90 | +31.1 | +1.13% | 1.08M | NASDAQ | |||
| 61.97 | 63.08 | 61.62 | -0.14 | -0.23% | 7.55M | NYSE | |||
| 248.12 | 252.59 | 239.25 | +16.46 | +7.11% | 31.07M | NASDAQ | |||
| 47.98 | 49.44 | 47.99 | -1.42 | -2.88% | 35.42M | NASDAQ | |||
| 169.42 | 174.86 | 168.88 | -6.75 | -3.83% | 10.40M | NYSE | |||
| 330.48 | 351.00 | 330.30 | -45.85 | -12.18% | 5.50M | NYSE | |||
| 25.95 | 26.74 | 25.39 | +0.54 | +2.13% | 35.41M | NYSE | |||
| 242.11 | 249.88 | 241.18 | -4.77 | -1.93% | 7.94M | NASDAQ | |||
| 28.20 | 28.63 | 28.15 | -0.02 | -0.07% | 3.83M | NASDAQ | |||
| 263.52 | 270.16 | 262.69 | +1.52 | +0.58% | 4.10M | NYSE | |||
| 36.13 | 37.03 | 36.03 | -0.70 | -1.90% | 12.48M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 345.80 | 356.69 | 342.53 | -3.76 | -1.08% | 4.57M | NASDAQ |
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California. As of November 16, 2020, MyoKardia, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.